Lazela (Ranolazine)

Ranolazine blocks the late inward sodium current in heart muscle cells, lowering intracellular sodium. This action reduces calcium overload, leading to better relaxation of the heart muscle, improved coronary perfusion, and a decrease in the heart’s oxygen consumption during stress.

The exact dosage of Lazela is determined by the prescribing clinician based on the individual’s clinical condition, renal function, and response to therapy. Physicians typically start with a low dose and may adjust it to achieve optimal symptom control while monitoring safety.

Ranolazine’s safety category in pregnancy is not clearly established, and limited data are available for lactating women. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Lazela, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Unlike beta‑blockers or nitrates, ranolazine does not significantly affect heart rate or blood pressure. It is often added when standard therapies are insufficient, offering a different mechanism—late sodium current inhibition—that can improve angina control without the hemodynamic effects seen with some alternatives.

Lazela should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Lazela is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a full glass of water and not crushed or chewed, unless the prescribing information specifically allows an alternative method.

The most critical safety concerns include QT interval prolongation, which can lead to life‑threatening ventricular arrhythmias, severe hypotension, and hepatic dysfunction. Patients should be monitored for cardiac rhythm changes and liver function abnormalities during treatment.

Lazela is contraindicated in individuals with known prolonged QT interval, congenital long‑QT syndrome, severe hepatic impairment, or those taking other medications that markedly prolong the QT interval. It should also be avoided in patients with a history of serious arrhythmias unless closely supervised.